Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

pharmiweb.com today archive

3222 PWToday Stories

Lundbeck - Double digit revenue growth

14 May 09

H. Lundbeck A/S reports highest ever quarterly revenue of DKK 3,226 million, a growth of 15% in constant exchange rates, driven by strong growth in Cipralex®, Ebixa® and Azilect®. The divestment of LifeCycle Pharma contributes DKK 124 million to first quarter revenue.


In mid-March Lundbeck acquired Ovation Pharmaceuticals, Inc. The first new product from this acquisition - ATryn® - was launched in May.


Research & Development costs were DKK 717 million in the period, up 37% compared with Q1 2008, driven by increased investment in the late-stage pipeline. R&D costs now correspond to 22% of total revenue.

Profit from operations (EBIT) was DKK 947 million, corresponding to an EBIT margin of 29%. Operating profit before depreciation and amortisation (EBITDA) was DKK 1,079 million.

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.